Literature DB >> 29778774

Continuous opioid substitution treatment over five years: Heroin use trajectories and outcomes.

Brian Eastwood1, John Strang2, John Marsden3.   

Abstract

BACKGROUND: This is the first national study in England of continuous long-term opioid substitution treatment (OST).
METHODS: All adults were admitted to community OST for opioid use disorder (OUD) in 2008/09 with continuous enrolment to 2013/14 (n = 7719). Heroin use trajectories were identified by multilevel Latent Class Growth Analysis. In Year 6 and 7 of follow-up, the outcome measure (analysed by multilevel, multivariable logistic regression) was 'successful completion and no re-presentation' (SCNR) to community treatment within six months.
RESULTS: Five heroin use trajectory classes were identified: 'gradual decreasing' (20.9%), 'decreasing then increasing' (21.7%), 'continued low-level' (17.0%), 'rapid decreasing' (25.6%), and 'continued high-level' (14.8%). At the end of Year 7, 4616 people (60.3%) remained in OST. Of those discharged, 28.8% achieved the SCNR follow-up outcome. SCNR was more likely in the 'gradual decreasing' (adjusted odds ratio [AOR] 2.40; 95% confidence interval [CI] 1.77-3.26), 'continued low-level' (AOR 2.46; CI 1.78-3.40), and 'rapid decreasing' (AOR 3.40; CI 2.43-4.37) classes relative to the 'continued high-level' class. SCNR was more likely among patients employed at admission (AOR 1.45; 95% CI 1.15-1.83) and those receiving adjunctive psychosocial interventions (AOR 1.44; 95% CI 1.03 to 2.02).
CONCLUSIONS: Among English patients in OST for 5 years, heroin use trajectories were clearly delineated with a gradient of response on the study outcome. Successful completion and no re-presentation was achieved by 28.8% of discharged patients. The rapid decreasing trajectory had the greatest likelihood of positive outcome. Adjunctive psychosocial intervention during OST was associated with positive outcome. Crown
Copyright © 2018. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Developmental trajectory; National; Opioid use disorder; Treatment effectiveness

Mesh:

Year:  2018        PMID: 29778774     DOI: 10.1016/j.drugalcdep.2018.03.052

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  8 in total

1.  Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone.

Authors:  Lesia M Ruglass; Jennifer Scodes; Martina Pavlicova; Aimee N C Campbell; Skye Fitzpatrick; Celestina Barbosa-Leiker; Kathleen Burlew; Shelly F Greenfield; John Rotrosen; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2019-10-21       Impact factor: 4.492

Review 2.  Longitudinal K-means approaches to clustering and analyzing EHR opioid use trajectories for clinical subtypes.

Authors:  Sarah Mullin; Jaroslaw Zola; Robert Lee; Jinwei Hu; Brianne MacKenzie; Arlen Brickman; Gabriel Anaya; Shyamashree Sinha; Angie Li; Peter L Elkin
Journal:  J Biomed Inform       Date:  2021-08-16       Impact factor: 8.000

3.  The subjective experience of heroin effects among individuals with chronic opioid use: Revisiting reinforcement in an exploratory study.

Authors:  Suky Martinez; Laura Brandt; Sandra D Comer; Frances R Levin; Jermaine D Jones
Journal:  Addict Neurosci       Date:  2022-08-28

4.  Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?

Authors:  John Marsden; Betty Tai; Robert Ali; Lian Hu; A John Rush; Nora Volkow
Journal:  Addiction       Date:  2019-01-30       Impact factor: 6.526

5.  Inpatient Opioid Use Disorder and Social Determinants of Health: A Nationwide Analysis of the National Inpatient Sample (2012-2014 and 2016-2017).

Authors:  Saanie Sulley; Memory Ndanga
Journal:  Cureus       Date:  2020-11-03

6.  Structural violence and the need for compassionate use of methadone in Mexico.

Authors:  Martha Romero-Mendoza; Ingris Peláez-Ballestas; Ariagor Manuel Almanza-Avendaño; Emilia Figueroa
Journal:  BMC Public Health       Date:  2022-03-29       Impact factor: 3.295

7.  Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone.

Authors:  John Marsden; Mike Kelleher; Eilish Gilvarry; Luke Mitcheson; Zoë Hoare; Dyfrig Hughes; Jatinder Bisla; Angela Cape; Fiona Cowden; Edward Day; Jonathan Dewhurst; Rachel Evans; Andrea Hearn; Joanna Kelly; Natalie Lowry; Martin McCusker; Caroline Murphy; Robert Murray; Tracey Myton; Sophie Quarshie; Gemma Scott; Sophie Turner; Rob Vanderwaal; April Wareham
Journal:  Trials       Date:  2022-08-19       Impact factor: 2.728

8.  Prospective Study on Factors Associated with Referral of Patients with Opioid Maintenance Therapy from Specialized Addictive Disorders Centers to Primary Care.

Authors:  Morgane Guillou-Landreat; Philippe Levassor; Marylène Guerlais; Veronique Sebille; Caroline Victorri-Vigneau
Journal:  Int J Environ Res Public Health       Date:  2021-05-27       Impact factor: 3.390

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.